[go: up one dir, main page]

WO2025125576A3 - Inhibitors of expression and/or function - Google Patents

Inhibitors of expression and/or function

Info

Publication number
WO2025125576A3
WO2025125576A3 PCT/EP2024/086234 EP2024086234W WO2025125576A3 WO 2025125576 A3 WO2025125576 A3 WO 2025125576A3 EP 2024086234 W EP2024086234 W EP 2024086234W WO 2025125576 A3 WO2025125576 A3 WO 2025125576A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
expression
function
disease
disorder associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/086234
Other languages
French (fr)
Other versions
WO2025125576A2 (en
Inventor
Natalie PURSELL
Alan VICTOR WHITMORE
Sophia MALANDRAKI-MILLER
Ines DE SANTIAGO
Gaye SAGINC GIANNOUSTAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
E Therapeutics PLC
Original Assignee
E Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2024/052934 external-priority patent/WO2024165571A2/en
Application filed by E Therapeutics PLC filed Critical E Therapeutics PLC
Priority to PCT/EP2024/088248 priority Critical patent/WO2025133348A1/en
Publication of WO2025125576A2 publication Critical patent/WO2025125576A2/en
Publication of WO2025125576A3 publication Critical patent/WO2025125576A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a metabolic disease or disorder, such as a metabolic disease or disorder associated with non-alcoholic fatty liver disease (NAFLD), and/or obesity and/or a disease or disorder associated with adipogenesis.
PCT/EP2024/086234 2023-12-15 2024-12-13 Inhibitors of expression and/or function Pending WO2025125576A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2024/088248 WO2025133348A1 (en) 2023-12-22 2024-12-20 Inhibitors of expression and/or function

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP23217288 2023-12-15
EP23217288.2 2023-12-15
EPPCT/EP2024/052934 2024-02-06
PCT/EP2024/052934 WO2024165571A2 (en) 2023-02-06 2024-02-06 Inhibitors of expression and/or function

Publications (2)

Publication Number Publication Date
WO2025125576A2 WO2025125576A2 (en) 2025-06-19
WO2025125576A3 true WO2025125576A3 (en) 2025-08-14

Family

ID=94128391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/086234 Pending WO2025125576A2 (en) 2023-12-15 2024-12-13 Inhibitors of expression and/or function

Country Status (1)

Country Link
WO (1) WO2025125576A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005786A2 (en) * 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
WO2011084193A1 (en) * 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2012005898A2 (en) * 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
KR20150086442A (en) * 2014-01-17 2015-07-28 주식회사 바이오인프라 Composition for overcoming resistance to her2 inhibitor comprising ant2 sirna
WO2019051402A1 (en) * 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
WO2024165571A2 (en) * 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CZ300837B6 (en) 1996-08-30 2009-08-26 Novo Nordisk A/S GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use
EP1062240B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S N-terminally modified glp-1 derivatives
DE69942306D1 (en) 1998-02-27 2010-06-10 Novo Nordisk As ABSTRACT OF GLP-1 ANALOG
DE69916811T2 (en) 1998-02-27 2005-04-14 Novo Nordisk A/S GLP-1 DERIVATIVES HAVING A HELIX CONTENT OVER 25% FOR PARTIALLY MADE STRUCTURED MICRO-SPECIFIC AGGREGATES
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
KR20060135661A (en) 2003-12-18 2006-12-29 노보 노르디스크 에이/에스 Novel glp-1 compounds
KR20060109940A (en) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 Novel glp-1 analogues linked to albumin-like agents
EP1765408B1 (en) 2004-07-08 2015-12-09 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
EP1799711B1 (en) 2004-10-07 2012-06-20 Novo Nordisk A/S Protracted exendin-4 compounds
JP2008515856A (en) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ Delayed GLP-1 compound
MX2007011307A (en) 2005-03-18 2007-10-08 Novo Nordisk As Extended glp-1 compounds.
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
GB0606212D0 (en) 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
BRPI0807728A2 (en) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp glucagon / glp-1 receptor co-agonists
JP5476304B2 (en) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス Glucagon-like peptide-1 derivatives and their pharmaceutical use
ES2532116T3 (en) 2007-09-05 2015-03-24 Novo Nordisk A/S Peptides derived with A-B-C-D and their therapeutic uses
EP2190873B1 (en) 2007-09-05 2015-07-22 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
GB0724478D0 (en) 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
SG192405A1 (en) 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
CN102123723B (en) 2008-06-17 2016-05-25 印第安纳大学研究及科技有限公司 Glucagon/GLP-1 receptor co-agonists
JP2012529463A (en) 2009-06-11 2012-11-22 ノヴォ ノルディスク アー／エス Combination of GLP-1 and FGF21 for treating type 2 diabetes
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
UY33462A (en) 2010-06-23 2012-01-31 Zealand Pharma As GLUCAGON ANALOGS
CN103764673A (en) 2011-06-10 2014-04-30 北京韩美药品有限公司 Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
AU2013255751B2 (en) 2012-05-03 2017-10-05 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
HK1207097A1 (en) 2012-09-07 2016-01-22 Sanofi Fusion proteins for treating a metabolic syndrome
CA3111317C (en) 2012-09-17 2023-08-29 F. Hoffmann-La Roche Ltd. Method of synthesizing thyroid hormone analogs and polymorphs thereof
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
TWI674270B (en) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
HRP20181300T1 (en) 2012-12-21 2018-10-05 Sanofi Exendin-4 derivatives as dual glp1/gip/glucagon agonists
UA118558C2 (en) 2013-05-28 2019-02-11 Такеда Фармасьютікал Компані Лімітед Peptide compound
HK1226084A1 (en) 2013-08-16 2017-09-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10689429B2 (en) 2014-04-07 2020-06-23 Novo Nordisk A/S Double-acylated GLP-1 compounds
JOP20200119A1 (en) 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
CN115181175A (en) 2016-04-22 2022-10-14 深圳市图微安创科技开发有限公司 GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis
TW201832783A (en) 2016-12-02 2018-09-16 法商賽諾菲公司 Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
JP7309606B2 (en) 2016-12-22 2023-07-18 サノフイ FGF21 Compound/GLP-1R Agonist Combinations with Optimized Activity Ratios
EP4470551A3 (en) 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
WO2019193144A1 (en) 2018-04-05 2019-10-10 Silence Therapeutics Gmbh siRNAs WITH VINYLPHOSPHONATE AT THE 5' END OF THE ANTISENSE STRAND
WO2019030268A1 (en) 2017-08-09 2019-02-14 Sanofi Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
AU2018338184B2 (en) 2017-09-25 2023-04-13 Merck Sharp & Dohme Llc Long-acting co-agonists of the glucagon and GLP-1 receptors
CN111465773B (en) 2017-12-22 2021-11-02 瓦林格创新股份有限公司 Panel set, method for assembling the same and locking device for furniture product
US20210275643A1 (en) 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
CA3178366A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds
EP4093757A1 (en) 2020-01-23 2022-11-30 Eli Lilly and Company Gip/glp1 co-agonist compounds
JP7777085B2 (en) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー／エス Solid Composition Comprising a GLP-1 Agonist and Histidine - Patent application
TW202216746A (en) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 Long acting glp-1/gip dual agonists
EP4175660A1 (en) 2020-07-02 2023-05-10 Sanofi Glp-1r agonist / fgf21 fusion proteins
BR112023000229A2 (en) 2020-07-22 2023-01-31 Novo Nordisk As COMPOUND, PHARMACEUTICAL COMPOSITION, AND, PEPTIDE
TW202229323A (en) 2020-10-17 2022-08-01 印度商太陽製藥工業有限公司 Novel glp-1/gip dual agonists
US20230391845A1 (en) 2020-10-30 2023-12-07 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
CN115572326B (en) 2021-06-21 2025-01-10 广东东阳光药业股份有限公司 Triple agonist of GLP-1, GCG and GIP receptors
MX2024001276A (en) 2021-07-30 2024-02-15 Boehringer Ingelheim Int Dose regimen for long-acting glp1/glucagon receptor agonists.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005786A2 (en) * 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
WO2011084193A1 (en) * 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2012005898A2 (en) * 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
KR20150086442A (en) * 2014-01-17 2015-07-28 주식회사 바이오인프라 Composition for overcoming resistance to her2 inhibitor comprising ant2 sirna
WO2019051402A1 (en) * 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
WO2024165571A2 (en) * 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Material Safety Data Sheet: Adenine Nucleotide Translocator 2 Antibody BIOTIN", 21 April 2021 (2021-04-21), XP093159712, Retrieved from the Internet <URL:https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FBID%2FSDS%2FANT2-BIOTIN%20MSDS.pdf> *
JANINA-MIRIAM NOY: "Direct Polymerization of the Arsenic Drug PENAO to Obtain Nanoparticles with High Thiol-Reactivity and Anti-Cancer Efficiency", BIOCONJUGATE CHEMISTRY, vol. 29, no. 2, 18 January 2018 (2018-01-18), US, pages 546 - 558, XP093160098, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00032 *
JANITH A. SENEVIRATNE: "Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma", vol. 152, no. 7, 8 November 2022 (2022-11-08), US, pages 1399 - 1413, XP093159664, ISSN: 0020-7136, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ijc.34349> DOI: 10.1002/ijc.34349 *
JONG BAE SEO: "Knockdown of ANT2 reduces adipocyte hypoxia and improves insulin resistance in obesity", vol. 1, no. 1, 19 November 2018 (2018-11-19), pages 86 - 97, XP093159888, ISSN: 2522-5812, Retrieved from the Internet <URL:https://www.nature.com/articles/s42255-018-0003-x.pdf> DOI: 10.1038/s42255-018-0003-x *
JOONSEOK CHO: "Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance", vol. 8, no. 1, 16 February 2017 (2017-02-16), UK, XP093159877, ISSN: 2041-1723, Retrieved from the Internet <URL:https://www.nature.com/articles/ncomms14477> DOI: 10.1038/ncomms14477 *
LE BRAS MORGANE ET AL: "Chemosensitization by knockdown of adenine nucleotide translocase-2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 66, no. 18, 15 September 2006 (2006-09-15), pages 9143 - 9152, XP002603476, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-4407 *
LI MING-HSIN ET AL: "Ligand Characteristics Important to Avidity Interactions of Multivalent Nanoparticles", BIOCONJUGATE CHEMISTRY, vol. 28, no. 6, 11 April 2017 (2017-04-11), US, pages 1649 - 1657, XP055917014, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00098 *
SHENGLONG ZHU: "Slc25a5 regulates adipogenesis by modulating ERK signaling in OP9 cells", vol. 27, no. 1, 2 February 2022 (2022-02-02), PL, XP093159660, ISSN: 1425-8153, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s11658-022-00314-y/fulltext.html> DOI: 10.1186/s11658-022-00314-y *
TAKAHIRO IKEDA: "Genistein regulates adipogenesis by blocking the function of adenine nucleotide translocase-2 in the mitochondria", vol. 86, no. 2, 29 November 2021 (2021-11-29), GB, pages 260 - 272, XP093159878, ISSN: 1347-6947, Retrieved from the Internet <URL:https://academic.oup.com/bbb/article-pdf/86/2/260/42565332/zbab203.pdf> DOI: 10.1093/bbb/zbab203 *

Also Published As

Publication number Publication date
WO2025125576A2 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
WO2024165571A3 (en) Inhibitors of expression and/or function
SA521430550B1 (en) GLP-1R Agonists and Uses Thereof
CU20210042A7 (en) Glp-1r agonists
MXPA05009933A (en) Compositions comprising fatty acids and amino acids.
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
SG170120A1 (en) Compositions containing riboflavin and sesamin-class compounds
MY177974A (en) A pharmaceutical composition for prevention of diet induced obesity
CA2374958A1 (en) Compositions normalizing circadian rhythm
MX2023005550A (en) Dichlorophenol hsd17b13 inhibitors and uses thereof.
WO2018108931A3 (en) Nutritional compositions containing butyrate and/or lactoferrin and uses thereof
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
EP1508335A4 (en) COMPOSITION AGAINST PERIODONTAL BACTERIA, AS WELL AS FOOD, BEVERAGES AND DENTAL WATER CONTAINING THE COMPOSITION AGAINST PERIODONTAL BACTERIA
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
MX2021005120A (en) Aerosolised formulation.
WO2025125576A3 (en) Inhibitors of expression and/or function
MX2023005142A (en) Use of fructosyltransferase.
EA202092057A1 (en) LIVER PROTECTIVE COMPOSITIONS AND THERAPEUTIC APPLICATIONS
MX2025009171A (en) Inhibitors of expression and/or function
CR20230452A (en) Incretin analog-containing compositions and uses thereof
WO2016085321A3 (en) Composition comprising a pentose and polyphenolic compound
MX2022011128A (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS.
MX2025002143A (en) Novel combination of steviol glycosides
WO2018078599A3 (en) Composition for the preventive or curative treatment of liver disorders
WO2007036809A3 (en) Novel acetylsalicylic acid formulations
WO2024245930A3 (en) Inhibitors of expression and/or function

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24829095

Country of ref document: EP

Kind code of ref document: A2